Doris is the President and CEO of OncoPep, Inc, a biotech company developing therapeutic cancer vaccines. Prior to joining OncoPep, Doris was the President and CEO of Healagenics, a privately held bio-medical device company where she launched their first commercial product for the treatment of chronic wounds. She has an extensive background in product development, operations and marketing within the life sciences including senior management roles at Antigenics and Genzyme Tissue Repair. Doris is an active member of the MIT Venture Mentoring Service and Boston University's Kindle Program.
Phil is a Lecturer at Babson College in the Technology, Operations, and Information Management division. He is responsible for undergraduate and graduate level courses in Operations and Supply Chain management, with a specialization in topics concerning healthcare supply chains. Prior to Babson, Phil enjoyed 30 years of experience with rapid growth and early stage Medical Device companies. He served as the Chief Operating Officer of ConforMIS, Inc., a producer of patient-specific orthopedic implants in Burlington, MA., and as COO of the high growth producer of home dialysis systems, NxStage Medical. Phil helped lead NxStage through its initial public offering and scale-up of its global production and supply chain capacity. His earlier experience included senior executive positions with Boston Scientific Corp and Roche Pharmaceuticals. Throughout his career, Phil's functional specialization has included global supply chain management, manufacturing operations and management of product development teams. Phil has an undergraduate degree in Biomedical Engineering and an MBA from the University of Chicago Booth School of Business.
Sarah is Executive Chairman of Millennium Prevention Inc., which combines serious science with web-enabled platforms and apps that link consumers and providers to improve health and wellness outcomes. She is also President Emeritus of Decision Resources Inc., a leading research and advisory firm focusing in health care. The company is best known for its therapeutically-focused analyses of global pharmaceutical, biotechnology and medical device markets and for its research on the U.S. managed care industry. Previously, Sarah was a Vice President at Arthur D. Little, Inc., from which she and Sam Fleming led a buyout of Arthur D. Little Decision Resources in 1990. Sarah holds a B.A. from the University of Pennsylvania and an A.M. from Harvard University.